Biomarkers of response to NAE inhibitors

Patent metadata

Field	Value
Publication number	US-10953013-B2
Application number	US-201615173393-A
Country	US
Kind code	B2
Filing date	Jun 3, 2016
Priority date	Oct 28, 2011
Publication date	Mar 23, 2021
Grant date	Mar 23, 2021

Abstract

Disclosed herein are markers whose mutational status is associated with sensitivity to treatment with NAE inhibitors. Mutational status is determined by measurement of characteristics of markers associated with the marker genes. Compositions and methods are provided to assess markers of marker genes to predict response to NAE inhibition treatment.

First claim

What is claimed:

1. A method of treating cancer, comprising
a) detecting, in a human subject, the presence of an inactivating mutation in at least one human marker gene, wherein the at least one marker gene is human tumor protein p53 (TP53) having a sequence of SEQ ID NO:15;
b) administering ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulphamate or a pharmaceutically acceptable salt thereof, to the subject having the mutation;
c) obtaining a tumor sample from the subject after administering the ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulphamate or a pharmaceutically acceptable salt thereof;
d) detecting the presence or absence of an inactivating mutation in at least one human marker gene in the tumor sample, wherein the at least one human marker gene is human TP53 having a sequence of SEQ ID NO:15; and
e) continuing to administer the ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulphamate or a pharmaceutically acceptable salt thereof to the subject when the mutation is detected.

2. The method of claim 1 , wherein the pharmaceutically acceptable salt is a hydrochloride salt.

3. The method of claim 1 , wherein the cancer is a hematological cancer or a solid tumor cancer.

4. The method of claim 3 , wherein the solid tumor cancer is head and neck cancer.

5. The method of claim 3 , wherein the hematological cancer is selected from the group consisting of multiple myeloma, acute myelogenous leukemia, Waldenstrom's syndrome, chronic lymphocytic leukemia, chronic myelogenous leukemia, B-cell lymphoma, non-Hodgkin's lymphoma, Hodgkin's lymphoma, and myelodysplastic syndrome.

6. A method of treating cancer, comprising
a) detecting, in a human subject, the absence of a mutation in a TP53 sequence of SEQ ID NO:15,
b) administering ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulphamate or a pharmaceutically acceptable salt thereof, to the subject;
c) obtaining a tumor sample from the subject after administering the ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulphamate or a pharmaceutically acceptable salt thereof;
d) detecting the presence or absence of a mutation in at least one human marker gene in the tumor sample, wherein the at least one human marker gene is human TP53 having a sequence of SEQ ID NO:15; and
e) continuing to administer the ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulphamate or a pharmaceutically acceptable salt thereof to the subject when a mutation is absent.

7. The method of claim 6 , wherein the pharmaceutically acceptable salt is a hydrochloride salt.

8. The method of claim 6 , wherein the cancer is a hematological cancer or a solid tumor cancer.

9. The method of claim 8 , wherein the solid tumor cancer is cervical cancer.

10. The method of claim 8 , wherein the solid tumor cancer is skin cancer.

11. The method of claim 8 , wherein the solid tumor cancer is CNS cancer.

12. The method of claim 8 , wherein the hematological cancer is selected from the group consisting of multiple myeloma, acute myelogenous leukemia, Waldenstrom's syndrome, chronic lymphocytic leukemia, chronic myelogenous leukemia, B-cell lymphoma, non-Hodgkin's lymphoma, Hodgkin's lymphoma, and myelodysplastic syndrome.

Assignees

• Millennium Pharm Inc
• Massachusetts Gen Hospital

Inventors

• Benes Cyril H
• Blakemore Stephen J
• Blank Jonathan L
• Lightcap Eric S
• Mulligan George J
• Schu Matthew C
• Smith Peter G
• Settleman Jeffrey E

Classifications

• G01N33/5758

  involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites · CPC title

• A61K31/519 Primary

  ortho- or peri-condensed with heterocyclic rings · CPC title

• G01N2800/60

  Complex ways of combining multiple protein biomarkers for diagnosis · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• C12Q2600/156

  Polymorphic or mutational markers · CPC title